Pelthos to Merge with Castle Creek in Rare Skin Disease Push

Pelthos Therapeutics and Castle Creek Biosciences have agreed to merge, bringing together their dermatology products and cell and gene therapy programmes to develop treatments for serious skin diseases.

The companies announced on October 30, 2026, that they had signed a definitive merger agreement. The deal will combine Pelthos’ commercial dermatology business with Castle Creek’s late-stage pipeline, led by D-Fi, an investigational gene-modified cell therapy for dystrophic epidermolysis bullosa (DEB), a rare and painful inherited skin disorder.

Following the merger, the combined company will continue operating as Pelthos Therapeutics Inc. and remain listed on the NYSE American under the ticker symbol PTHS.

D-Fi, also known as dabocemagene autoficel or FCX-007, is being developed to treat DEB, a condition caused by mutations in the COL7A1 gene. These mutations affect the production of type VII collagen, a protein that helps hold the skin’s layers together. People living with the condition can develop painful, long-lasting wounds and face an increased risk of skin cancer.

The treatment uses a patient’s own skin cells, called fibroblasts, which are genetically modified to produce type VII collagen. The modified cells are then injected into affected areas of the skin. Castle Creek plans to continue the Phase 3 clinical programme for D-Fi. The treatment has received Orphan Drug Designation from the US Food and Drug Administration (FDA), along with Fast Track and Regenerative Medicine Advanced Therapy designations for recessive DEB.

Castle Creek is also exploring a topical version of D-Fi and plans to use its fibroblast technology to develop treatments for other serious skin conditions, including certain cancers and inflammatory diseases.

The merger will give Pelthos access to Castle Creek’s cell and gene therapy platform, while Castle Creek will benefit from Pelthos’ existing commercial capabilities and experience in dermatology. Pelthos currently has three FDA-approved products: ZELSUVMI for molluscum contagiosum, XEPI for impetigo and XEGLYZE for head lice.

The companies believe their combined expertise could help advance D-Fi towards potential commercialisation and support the development of additional treatments. The deal will also expand Pelthos beyond its current focus on skin infections into rare genetic and other serious skin diseases.

Under the agreement, Castle Creek stockholders will receive 5.2 million shares of Pelthos common stock when the transaction closes. This will represent approximately 32.5% of Pelthos’ fully diluted shares.

Castle Creek stockholders may also receive up to 5.8 million additional Pelthos shares if D-Fi receives FDA approval. The agreement includes up to $300 million in milestone payments, subject to development and commercial targets. This includes $50 million linked to the achievement of specified Phase 3 clinical endpoints and up to $250 million tied to D-Fi’s first commercial sale and future sales performance. Castle Creek stockholders will also be entitled to 80% of the net proceeds if a priority review voucher is awarded for D-Fi and subsequently sold.

The boards of both companies have approved the transaction. It is expected to close by the end of the first quarter of 2027, subject to customary closing conditions, including approval from Castle Creek stockholders.

Scott Plesha will continue as Chief Executive Officer of the combined company, while Peter Greenleaf will serve as Executive Chair.

For Pelthos, the deal represents a move into a broader range of dermatology treatments and adds a late-stage gene therapy programme to its existing commercial portfolio. For Castle Creek, the merger provides access to an established commercial organisation as it works to advance D-Fi and expand its development pipeline.

The success of the combination will depend in part on the continued clinical development of D-Fi, regulatory progress and the ability to bring new treatments to patients with serious skin diseases.

You might also like